Richard Weaver’s article on the need for the increasing need for DMPK influence in discovering new medicines has been published in the latest edition of the European Biopharmaceutical Review.
One of the largest challenges of bringing new medicines to market is how to reduce the rates of attrition due to lack of efficacy and safety profile, whilst managing costs. In this article, Richard discusses the influence of drug metabolism and pharmacokinetics and how critical this is to responding to these challenges, as well as understanding the exposure of a compound or drug.
To read the full article, click here.
This article is taken from European Biopharmaceutical Review October 2017, pages 60-65. © Samedan Ltd